title: Activation of κ opioid receptors increases intrinsic excitability of dentate gyrus granule cells.
abstract: The dentate gyrus of the hippocampus is thought to control information flow into the rest of the hippocampus. Under pathological conditions, such as epilepsy, this protective feature is circumvented and uninhibited activity flows throughout the hippocampus. Many factors can modulate excitability of the dentate gyrus and ultimately, the hippocampus. It is therefore of critical importance to understand the mechanisms involved in regulating excitability in the dentate gyrus. Dynorphin, the endogenous ligand for the kappa (κ) opioid receptor (KOR), is thought to be involved in neuromodulation in the dentate gyrus. Both dynorphin and its receptor are widely expressed in the dentate gyrus and have been implicated in epilepsy and other complex behaviours such as stress-induced deficits in learning and stress-induced depression-like behaviours. Administration of KOR agonists can prevent both the behavioural and electroencephalographic measures of seizures in several different models of epilepsy. Antagonism of the KORs also prevents stress-induced behaviours. This evidence suggests the KORs as possible therapeutic targets for various pathological conditions. In addition, KOR agonists prevent the induction of LTP. Although there are several mechanisms through which dynorphin could mediate these effects, no studies to date investigated the effects of KOR activation on intrinsic membrane properties and cell excitability. We used whole-cell, patch-clamp recordings from acute mouse hippocampus slices to investigate the effect of KOR activation on dentate gyrus granule cell excitability. The agonist U69,593 (U6, 1 μM) resulted in a lower spike threshold, a decreased latency to first spike, an increased spike half-width, and an overall increase in spike number with current injections ranging from 15 to 45 pA. There was also a reduction in the interspike interval (ISI) both early and late in the spike train, with no change in membrane potential or input resistance. Preincubation of the slice with the selective KOR antagonist, nor-binalthorphimine (BNI, 1 μM) inhibited the effect of U6 on the latency to first spike and spike half-width suggesting that these effects are mediated through KORs. The inclusion of GDP-βS (1 mM) in the recording pipette prevented all of the U6 effects, suggesting that all effects are mediated via a G-protein-dependent mechanism. Inclusion of the A-type K+ current blocker, 4-aminopyridine (4-AP, 5 mM) in the pipette also antagonised the effects of U6. Kv4.2 is one of the channel α subunits thought to be responsible for carrying the A-type K+ current. Incubation of hippocampus slices with U6 resulted in a decrease in the Kv4.2 subunit protein at the cell surface. These results are consistent with an increase in cell excitability in response to KOR activation and may reflect new possibilities for additional opioid functions.
authors: Department of Cell and Molecular Biology, Tulane University, 6400 Freret St, New Orleans, LA 70118, USA.
authors: Carmel M
authors: CM
authors: McDermott
authors: Laura A
authors: LA
authors: Schrader
references: J Biol Chem. 1999 Apr 23;274(17):12087-94
references: 10207034
references: J Neurochem. 1991 Jul;57(1):333-43
references: 1675664
references: J Neurosci. 2002 Dec 1;22(23):10123-33
references: 12451113
references: J Pharmacol Exp Ther. 1986 Apr;237(1):49-53
references: 3007743
references: J Pharmacol Exp Ther. 1988 Feb;244(2):564-70
references: 2894454
references: Proc Natl Acad Sci U S A. 1983 Jan;80(2):589-93
references: 6132379
references: Proc Natl Acad Sci U S A. 1982 Sep;79(17):5435-7
references: 6127674
references: J Neurosci. 2008 Jul 23;28(30):7513-9
references: 18650329
references: NIDA Res Monogr. 1986;75:563-66
references: 2829003
references: J Neurochem. 2008 Jul;106(1):182-92
references: 18363830
references: J Neurophysiol. 1998 Feb;79(2):1081-91
references: 9463463
references: Nature. 2000 Feb 3;403(6769):553-6
references: 10676964
references: J Neurochem. 2004 Sep;90(5):1258-68
references: 15312181
references: J Neurosci. 1994 Aug;14(8):4740-7
references: 7913954
references: J Neurosci. 1992 Jan;12(1):132-41
references: 1345943
references: Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8366-71
references: 12048251
references: Jpn J Pharmacol. 1992 Apr;58(4):435-42
references: 1328733
references: J Neurosci. 2006 Nov 22;26(47):12143-51
references: 17122039
references: J Biol Chem. 2000 Feb 25;275(8):5337-46
references: 10681507
references: J Pharmacol Exp Ther. 1990 Nov;255(2):900-5
references: 1978733
references: J Comp Neurol. 1981 May 10;198(2):335-50
references: 6263955
references: J Comp Neurol. 1987 Jan 22;255(4):497-510
references: 2880880
references: J Neurosci. 2009 Apr 1;29(13):4293-300
references: 19339623
references: J Neurochem. 1997 Feb;68(2):616-24
references: 9003048
references: Neuron. 2007 Jun 21;54(6):933-47
references: 17582333
references: Neuron. 2008 Nov 26;60(4):657-71
references: 19038222
references: Neuropeptides. 2006 Apr;40(2):115-23
references: 16439015
references: Brain. 2007 Apr;130(Pt 4):1017-28
references: 17347252
references: Eur Neuropsychopharmacol. 1994 Dec;4(4):527-33
references: 7894264
references: Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10144-9
references: 12114547
references: J Neurosci. 2008 Jan 9;28(2):407-14
references: 18184783
references: J Neurosci. 1986 Oct;6(10):3094-102
references: 2876067
references: Neuron. 1995 Jun;14(6):1265-72
references: 7605635
references: Nature. 1997 Jun 26;387(6636):869-75
references: 9202119
references: Nat Neurosci. 2004 Feb;7(2):126-35
references: 14730307
references: Neuroscience. 1992 Nov;51(2):357-62
references: 1465197
references: Nature. 1982 Jul 15;298(5871):245-9
references: 6123953
references: Science. 1997 Jan 10;275(5297):209-13
references: 8985013
references: Brain Res Mol Brain Res. 1991 Jan;9(1-2):79-86
references: 1850080
references: J Neurosci. 2007 Oct 24;27(43):11614-23
references: 17959804
references: J Neurosci. 1998 May 15;18(10):3521-8
references: 9570783
references: J Biol Chem. 2003 Sep 5;278(36):34631-40
references: 12815037
references: J Neurosci. 1985 Mar;5(3):808-16
references: 3838345
references: Proc Natl Acad Sci U S A. 1983 Feb;80(3):891-4
references: 6131416
references: J Neurosci. 1988 Jun;8(6):1852-62
references: 2898512
references: J Neurosci. 1994 Feb;14(2):809-20
references: 7905518
references: J Biol Chem. 2007 Jan 12;282(2):1205-15
references: 17102134
references: Brain. 2006 Mar;129(Pt 3):642-54
references: 16399805
references: J Biol Chem. 1999 Aug 20;274(34):23802-7
references: 10446141
references: J Comp Neurol. 1996 Jul 01;370(3):377-95
references: 8799863
references: Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3216-21
references: 20133770
references: J Neurophysiol. 1999 Oct;82(4):1768-75
references: 10515966
references: J Neurophysiol. 1994 Oct;72(4):1697-705
references: 7823095
references: J Physiol. 1971 Feb;213(1):21-30
references: 5575340
references: J Pharmacol Exp Ther. 1984 Jan;228(1):88-93
references: 6141278
references: Nature. 1993 Jun 3;363(6428):451-4
references: 8099201
references: Neurosci Lett. 1986 Oct 30;71(1):31-6
references: 2878396
references: J Neurosci. 1995 Oct;15(10):6939-45
references: 7472450
references: Science. 1982 Jan 22;215(4531):413-5
references: 6120570
references: Life Sci. 1989;44(10):661-5
references: 2538689
references: Eur J Neurosci. 1995 Sep 1;7(9):1850-6
references: 8528458
references: J Neurosci. 2003 Jul 2;23(13):5674-83
references: 12843270
references: Proc Natl Acad Sci U S A. 1988 Jun;85(11):4061-5
references: 2836869
references: J Neurosci. 1994 Jun;14(6):3736-50
references: 7911518
references: Nature. 1993 Sep 9;365(6442):188
references: 8103916
references: J Physiol. 2005 Nov 15;569(Pt 1):41-57
references: 16141270
references: Life Sci. 1990;46(17):PL1-7
references: 2160036